Global life sciences companies, research institutes, and universities face unique challenges when complying with U.S. and non-U.S. trade control laws, including complying with general and specific licenses authorizing business in sanctioned countries, risks associated with restricted parties and screening, and the complex export control requirements related to pathogens, toxins, and other materials, equipment and technology associated with research and development activities.

Join us online for the timely panel discussion of these topics with trade compliance officials from leading global pharmaceutical and medical device companies.

The session will cover the following topics:

• Navigating the complex U.S. human rights sanctions that apply to Hong Kong and Xinjiang province, including the designation of the Xinjiang Production and Construction Corps (XPCC), which owns and controls hospitals in Xinjiang province.
• The most recent developments with regards to Iran sanctions, including COVID-19 related activities under General License N, conducting research and clinical trials in Iran, and avoiding common compliance pitfalls when engaging in financial transactions with Iranian parties, including the Central Bank of Iran.
• Assessing the export and deemed export issues related to conducting research and development activities related to controlled pathogens, toxins, related genetic materials, vaccines, and precursor chemicals.